Top 5 Stocks to Buy Now
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:GNPX

Genprex Q3 2025 Earnings Report

Genprex logo
$0.52 -0.03 (-5.29%)
Closing price 04:00 PM Eastern
Extended Trading
$0.52 0.00 (-0.77%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Genprex EPS Results

Actual EPS
-$5.00
Consensus EPS
-$12.50
Beat/Miss
Beat by +$7.50
One Year Ago EPS
N/A

Genprex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genprex Announcement Details

Quarter
Q3 2025
Date
11/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Genprex's next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules.

Conference Call Resources

Genprex Earnings Headlines

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 ...
June 22 at 11:57 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/genprex-receives-notice-allowance-canadian-130000079.html
Genprex Secures Canadian Patent for Reqorsa Lung Cancer Therapy
June 22 at 10:11 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-secures-canadian-patent-for-reqorsa-lung-cancer-therapy?utm_source=marketbeat.com&utm_medium=referral
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
June 23 at 1:00 AM  |  Altimetry (Ad)
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
June 22 at 9:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-receives-a-notice-of-allowance-from-the-canadian-intellectual-property-office-for-a-patent-claiming-the-combination-of-reqorsa-gene-therapy-with-either-pd-1-or-pd-l1-antibodies-to-treat-cancer-302804049.html
Genprex Shareholders Approve Expanded Equity Plan, Reverse Split
June 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-shareholders-approve-expanded-equity-plan-reverse-split?utm_source=marketbeat.com&utm_medium=referral
Genprex to Participate at BIO International Convention 2026
June 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-international-convention-2026-302802751.html
See More Genprex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email.

About Genprex

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes. This preclinical program seeks to deliver genes that support insulin production and glucose regulation, laying the groundwork for future clinical development in metabolic diseases. By leveraging its gene delivery platform, the company aims to expand its pipeline into other oncology and metabolic indications over time.

Headquartered in Austin, Texas, Genprex operates under a management team with deep experience in gene therapy research and biopharmaceutical development. The company collaborates with leading academic and clinical research centers to conduct its studies, ensuring rigorous trial design and patient enrollment. Through these partnerships, Genprex seeks to translate cutting-edge genetic science into transformative therapies for patients with high-unmet medical needs.

View Genprex Profile
Earnings Tools